{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:47:21Z","timestamp":1782377241288,"version":"3.54.5"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1617,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/jth.14017","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T17:44:56Z","timestamp":1523036696000},"page":"1028-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Use of direct oral anticoagulants in antiphospholipid syndrome"],"prefix":"10.1016","volume":"16","author":[{"given":"H.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Efthymiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14017_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10\u2010year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jth.14017_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"issue":"Suppl. 10","key":"10.1111\/jth.14017_bb0025","article-title":"Systemic lupus erythematosus: detailed anatomy of a cohort (follow\u2010up for more than 35 years)","volume":"68","author":"Del Carmelo Gracio Tello","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jth.14017_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jth.14017_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz\u2010Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.14017_bb0040","series-title":"Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights","first-page":"317","article-title":"15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report","author":"Andrade","year":"2017"},{"key":"10.1111\/jth.14017_bb0045","unstructured":"Pradaxa 150 mg hard capsules. Summary of Product Characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/24839 Accessed 15 February 2018."},{"key":"10.1111\/jth.14017_bb0050","unstructured":"Eliquis 5 mg film\u2010coated tablets film\u2010coated tablets. Summary of Product Characteristics. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/27220. Accessed 15 February 2018."},{"key":"10.1111\/jth.14017_bb0055","unstructured":"Lixiana 60 mg Film\u2010Coated Tablets. Summary of Product Characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/30506. Accessed 15 February 2018."},{"key":"10.1111\/jth.14017_bb0060","unstructured":"Xarelto 15 and 20 mg film\u2010coated tablets. Summary of Product Characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/25586. Accessed 14 February 2018."},{"key":"10.1111\/jth.14017_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high\u2010risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0070","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high\u2010risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.14017_bb0075","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz\u2010Irastorza","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jth.14017_bb0080","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.1997.00440390101013","article-title":"A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis","volume":"157","author":"Krnic\u2010Barrie","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.14017_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.14017_bb0090","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid\u2010antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"10.1111\/jth.14017_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14017_bb0105","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14017_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1111\/jth.14017_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence\u2010based recommendations for the prevention and long\u2010term management of thrombosis in antiphospholipid antibody\u2010positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz\u2010Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1111\/jth.14017_bb0120","unstructured":"Royal College of Obstetricians and Gynaecologists guidlines: reducing the risk of venous thromboembolism during pregnancy and puerperium. Green\u2010top guideline No. 37a. https:\/\/www.rcog.org.uk\/en\/guidelines-research-services\/guidelines\/gtg37a\/. 2015."},{"key":"10.1111\/jth.14017_bb0125","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14017_bb0130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1160\/TH07-05-0329","article-title":"Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women","volume":"98","author":"Bauersachs","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0135","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jth.14017_bb0140","unstructured":"Royal College of Physicians Intercollegiate Stroke Working Party. https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/stroke-guidelines"},{"key":"10.1111\/jth.14017_bb0145","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0150","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high\u2010intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo\u2010occlusive events in patients with ischemic stroke","volume":"291","author":"Levine","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/jth.14017_bb0160","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence\u2010based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14017_bb0165","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/1060028014546361","article-title":"A review of warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant","volume":"48","author":"Crowl","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.14017_bb0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2001.03178.x","article-title":"Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins","volume":"115","author":"Tripodi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14017_bb0175","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0180","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0185","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/jth.12917","article-title":"Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome","volume":"13","author":"Arachchillage","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jth.13266","article-title":"The laboratory's 2015 perspective on direct oral anticoagulant testing","volume":"14","author":"Gosselin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.14017_bb0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ijlh.12350","article-title":"Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory","volume":"37","author":"Gosselin","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.14017_bb0200","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ajcp\/aqx035","article-title":"The effects of indirect\u2010 and direct\u2010acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a Coagulation Reference Laboratory","volume":"147","author":"Seheult","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.14017_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"key":"10.1111\/jth.14017_bb0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent false\u2010positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.14017_bb0215","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1515\/cclm-2011-0888","article-title":"Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests","volume":"50","author":"Halbmayer","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1111\/jth.14017_bb0220","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","article-title":"Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time","volume":"9","author":"van","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0225","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MBC.0000000000000235","article-title":"False\u2010positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome","volume":"26","author":"Goralczyk","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14017_bb0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1160\/TH12-04-0228","article-title":"Ex vivo effects of low\u2010dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions","volume":"109","author":"Mani","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH10-08-0511","article-title":"Rivaroxaban and false positive lupus anticoagulant testing","volume":"105","author":"Merriman","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.14017_bb0245","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2009-09-244426","article-title":"Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants","volume":"115","author":"Devreese","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.14017_bb0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1160\/TH08-06-0393","article-title":"Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography","volume":"101","author":"Devreese","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0255","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2014.11.037","article-title":"Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in\u2010vivo markers of coagulation activation, in patients with venous thromboembolism","volume":"135","author":"Arachchillage","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0260","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/j.1538-7836.2007.02753.x","article-title":"Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants","volume":"5","author":"Samama","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0265","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","article-title":"Effect of the anti\u2010factor Xa and anti\u2010factor IIa activities of low\u2010molecular\u2010weight heparins upon the phases of thrombin generation","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20107939 \u2013 an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0275","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet\u2010induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.14017_bb0280","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.thromres.2011.07.026","article-title":"In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux","volume":"129","author":"Samama","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0285","first-page":"989","article-title":"Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban","volume":"111","author":"Herrmann","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0290","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MBC.0000000000000509","article-title":"An in\u2010vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor\u2010induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban","volume":"27","author":"Wan","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14017_bb0295","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.thromres.2015.03.032","article-title":"How the direct oral anticoagulant apixaban affects thrombin generation parameters","volume":"135","author":"Tripodi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0300","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20107939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.14017_bb0305","unstructured":"Genetic and Rare Diseases Information Center (GARD). https:\/\/rarediseases.info.nih.gov\/gard\/5824\/antiphospholipid-syndrome\/resources\/1. Accessed 15 February 2018."},{"key":"10.1111\/jth.14017_bb0310","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1111\/jth.14017_bb0315","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE\u2010COVER(R), RE\u2010COVER II, and RE\u2010MEDY","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"key":"10.1111\/jth.14017_bb0320","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0325","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0330","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0335","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0340","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-015-3030-y","article-title":"Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases","volume":"35","author":"Signorelli","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1111\/jth.14017_bb0345","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.thromres.2015.01.028","article-title":"The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases","volume":"135","author":"Son","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0350","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0961203317701841","article-title":"Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?","volume":"26","author":"Resseguier","year":"2017","journal-title":"Lupus"},{"key":"10.1111\/jth.14017_bb0355","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.autrev.2015.03.007","article-title":"Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome","volume":"14","author":"Noel","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1111\/jth.14017_bb0360","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2016.12.009","article-title":"The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome","volume":"152","author":"Malec","year":"2017","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0365","unstructured":"Unlu O, Cohen H, Cuadrado MJ, Fortin PR, Ramires de Jesus G, Gerosa M, Knight JK, Pengo V, Petri M, Rodriguez\u2010Almaraz E, Zuily S, Erkan D. OBOAA. Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients [abstract]. Arthritis Rheumatol 2016; 68 (suppl 10). http:\/\/acrabstracts.org\/abstract\/antiphospholipid-syndrome-alliance-for-clinical-trials-international-networking-registry-analysis-direct-oral-anticoagulant-use-among-antiphospholipid-syndrome-patients\/. Accessed May 10, 2018."},{"key":"10.1111\/jth.14017_bb0370","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MBC.0000000000000247","article-title":"Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism","volume":"26","author":"Sciascia","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14017_bb0375","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0961203315624555","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: a real life case series","volume":"25","author":"Betancur","year":"2016","journal-title":"Lupus"},{"key":"10.1111\/jth.14017_bb0380","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kep373","article-title":"Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti\u2010phospholipid antibodies: a meta\u2010analysis of randomized controlled trials and meta\u2010regression","volume":"49","author":"Mak","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jth.14017_bb0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low\u2010dose aspirin vs low\u2010dose aspirin plus low\u2010intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jth.14017_bb0390","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"10.1111\/jth.14017_bb0395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamainternmed.2013.3037","article-title":"Surrogate outcomes in clinical trials: a cautionary tale","volume":"173","author":"Svensson","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1111\/jth.14017_bb0400","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open\u2010label, phase 2\/3, non\u2010inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14017_bb0405","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(16)30107-7","article-title":"Rivaroxaban to treat thrombotic antiphospholipid syndrome","volume":"3","author":"Urbanus","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14017_bb0410","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.13475","article-title":"Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"14","author":"Arachchillage","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0415","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0961203315611495","article-title":"Efficacy and safety of rivaroxaban vs warfarin in high\u2010risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial","volume":"25","author":"Pengo","year":"2016","journal-title":"Lupus"},{"key":"10.1111\/jth.14017_bb0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with Antiphospholipid Syndrome: Study Rationale and Design (ASTRO\u2010APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.14017_bb0425","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0430","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1753944716643645","article-title":"Management of rivaroxaban in relation to bodyweight and body mass index","volume":"10","author":"Uprichard","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1111\/jth.14017_bb0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2016.09.010","article-title":"Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience","volume":"147","author":"Arachchillage","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14017_bb0440","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/rth2.12039","article-title":"The impact of body weight on rivaroxaban pharmacokinetics","volume":"1","author":"Barsam","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0445","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.12107","article-title":"Guideline on the management of bleeding in patients on antithrombotic agents","volume":"160","author":"Makris","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14017_bb0455","unstructured":"Praxbind 2.5 g\/50 mL solution for injection\/infusion. Summary of Product Characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5073. Accessed 14 February 2018."},{"key":"10.1111\/jth.14017_bb0460","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14017_bb0465","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature","volume":"18","author":"Dufrost","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/jth.14017_bb0470","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.contraception.2010.12.011","article-title":"Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation","volume":"84","author":"Huq","year":"2011","journal-title":"Contraception"},{"key":"10.1111\/jth.14017_bb0475","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.14017_bb0480","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer\u2010Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14017_bb0485","first-page":"CD002126","article-title":"Progesterone\/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.14017_bb0490","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1160\/TH16-04-0305","article-title":"Pregnancy outcome in patients exposed to direct oral anticoagulants \u2013 and the challenge of event reporting","volume":"116","author":"Beyer\u2010Westendorf","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14017_bb0495","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jth.13366","article-title":"Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH","volume":"14","author":"Cohen","year":"2016","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622011059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622011059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:20:53Z","timestamp":1761535253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622011059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1538783622011059"],"URL":"https:\/\/doi.org\/10.1111\/jth.14017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of direct oral anticoagulants in antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}